logo

Acadia Pharmaceuticals Inc (ACAD)



Trade ACAD now with
  Date
  Headline
8/31/2020 9:08:23 AM ACADIA Pharmaceuticals Appoints Gudarz Davar EVP And Head Of Research And Development
7/20/2020 4:05:55 PM ACADIA Says Phase 3 CLARITY Study On Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint
6/15/2020 9:10:32 AM ACADIA Submits SNDA For NUPLAZID For Treatment Of Hallucinations, Delusions Associated With Dementia-Related Psychosis
5/26/2020 9:12:07 AM ACADIA To Merge CLARITY-2, CLARITY-3 Phase 3 Studies showing Pimavanserin For Adjunctive Treatment Of MDD
3/3/2020 6:01:44 PM ACADIA Pharma, Neuren Pharma Announce RPD Designation For Trofinetide For Treatment Of Rett Syndrome
12/4/2019 8:53:27 PM ACADIA Presents Positive Results On Pimavanserin In Patients With Dementia-Related Psychosis
9/9/2019 6:41:29 AM ACADIA Says Phase 3 HARMONY Study Met Its Primary Endpoint
7/22/2019 4:11:22 PM ACADIA: Pimavanserin Didn't Achieve Statistical Significance On Primary Endpoint
5/18/2019 1:41:07 PM ACADIA To Present Phase 2 CLARITY Results For Pimavanserin As Adjunctive Treatment In Major Depressive Disorder
4/25/2019 9:04:17 AM ACADIA Pharmaceuticals Begins Phase 3 CLARITY Program
4/1/2019 9:05:39 AM ACADIA Promotes Elena Ridloff To EVP, CFO
11/30/2018 4:06:32 PM ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
11/27/2018 9:32:28 PM ACADIA Pharma Prices Underwritten Public Offering Of 16.18 Mln Shares At $17.00/shr